Critical limb ischemia
Critical limb ischemia (CLI), also referred to as limb threat, is an advanced stage of peripheral artery disease. It is defined as a triad of ischemic rest pain, arterial insufficiency ulcers, and gangrene. The latter two conditions are jointly referred to as tissue loss, reflecting the development of surface damage to the limb tissue due to the most severe stage of ischemia. CLI has a negative prognosis within a year after the initial diagnosis, with 1-year amputation rates of approximately 12% and mortality of 50% at 5 years and 70% at 10 years.[1]
CLI was conceived to identify patients at high-risk for major amputation, but the increasing prevalence of diabetes mellitus has led to a broader conception of limb threat that includes the risk of amputation associated with severely infected and non-healing wounds.[2]
Contents
Types
Critical limb ischemia is further subdivided into rest pain and tissue loss:
Rest pain
Rest pain is a continuous burning pain of the lower leg or feet. It begins, or is aggravated, after reclining or elevating the limb and is relieved by sitting or standing. It is more severe than intermittent claudication, which is also a pain in the legs from arterial insufficiency.
Tissue loss
Tissue loss is the development of arterial insufficiency ulcers or gangrene due to peripheral artery disease.
Diagnosis
Critical limb ischaemia is diagnosed by the presence of ischaemic rest pain, arterial insufficiency ulcers and gangrene. Other factors which may point to a diagnosis of critical limb ischaemia are a Buerger's angle of less than 20 degrees during Buerger's test, a capillary refill of more than 15 seconds or diminished or absent pulses.
Critical limb ischaemia is different from acute limb ischaemia. Acute limb ischaemia is a sudden lack of blood flow to the limb, for example caused by an embolus whereas critical limb ischaemia is a late sign of a progressive chronic disease.
Treatment
Treatment mirrors that of other symptoms of peripheral artery disease, and includes modifying risk factors, revascularization via vascular bypass or angioplasty, and in the case of tissue loss, wound debridement.
Research
In 2011 pCMV-vegf165 was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.[3][4]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
